RJA
PGNX

Raymond James & Associates’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Raymond James & Associates’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-45,470
Closed -$231K – 3812
2019
Q4 		$231K Buy
45,470
+12
+0% +$63 ﹤0.01% 3258
2019
Q3 		$230K Sell
45,458
-2,027
-4% -$10.1K ﹤0.01% 3174
2019
Q2 		$293K Sell
47,485
-10,336
-18% -$49.8K ﹤0.01% 3028
2019
Q1 		$268K Buy
57,821
+5,781
+11% +$26.2K ﹤0.01% 3046
2018
Q4 		$219K Sell
52,040
-6,058
-10% -$30.8K ﹤0.01% 3074
2018
Q3 		$364K Sell
58,098
-13,488
-19% -$104K ﹤0.01% 2913
2018
Q2 		$576K Buy
71,586
+14,008
+24% +$107K ﹤0.01% 2583
2018
Q1 		$430K Buy
57,578
+4,572
+9% +$30.4K ﹤0.01% 2656
2017
Q4 		$315K Sell
53,006
-372
-0.7% -$2.26K ﹤0.01% 2806
2017
Q3 		$393K Buy
53,378
+1,102
+2% +$7K ﹤0.01% 2625
2017
Q2 		$355K Buy
52,276
+4,599
+10% +$34K ﹤0.01% 2623
2017
Q1 		$450K Buy
47,677
+3,653
+8% +$36.5K ﹤0.01% 2451
2016
Q4 		$380K Buy
+44,024
New +$325K ﹤0.01% 2501

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Raymond James & Associates's PGNX Position: Q1 2020 in Review

Raymond James & Associates sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 45,470 shares — an estimated $231K sold.

Raymond James & Associates first reported a position in PGNX in Q4 2016 and held it in 13 quarters. The position peaked at $576K in Q2 2018. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Raymond James & Associates reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 45,470 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $231K.
  • Raymond James & Associates first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 13 quarters.
  • Raymond James & Associates's Progenics Pharmaceuticals Inc position peaked at $576K in Q2 2018.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.